APEX BIOVENTURES ACQUISITION CORP

Apex Bioventures Acquisition Corp, trading under the ticker PEX, filed its Form 424B4 final prospectus with the SEC on June 8, 2007, completing its initial public offering. The blank-check company was organized by an Apex-affiliated sponsor team with a stated focus on identifying acquisition targets in the life sciences and biotechnology sector. A 2007-vintage vehicle, PEX belongs to an early cohort of SPACs that operated well before the blank-check boom of 2020 and 2021, and has since run its full course as a publicly traded blank-check company. Sign up on SpacDesk for complete filing history, sponsor records, and deal outcomes across PEX and the broader SPAC universe.